Candel Therapeutics (CADL) Share-based Compensation (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Share-based Compensation data on file, last reported at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 3.7% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $3.8 million (down 28.14% YoY), and the FY2025 full-year result was $3.8 million, down 28.14% from the prior year.
• Share-based Compensation grew to $1.3 million in Q4 2025, from $1.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q3 2021 to a low of -$446000.0 in Q4 2021.
• A 5-year average of $874500.0 and a median of $841000.0 in 2022 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 2200.0% in 2021, while the deepest fall reached 125.44% in 2021.
• Tracing CADL's Share-based Compensation over 5 years: stood at -$446000.0 in 2021, then soared by 242.15% to $634000.0 in 2022, then soared by 48.11% to $939000.0 in 2023, then surged by 32.48% to $1.2 million in 2024, then advanced by 3.7% to $1.3 million in 2025.
• Business Quant data shows CADL's Share-based Compensation at $1.3 million in Q4 2025, $1.2 million in Q3 2025, and $1.0 million in Q2 2025.